轮状病毒疫苗对马达加斯加全因腹泻及轮状病毒住院的影响
马达加斯加于2014年5月将轮状病毒疫苗纳入扩大免疫规划,本研究分析了CHU MET医院5岁以下儿童疫苗接种前后全因腹泻患病率和轮状病毒住院趋势及循环基因型。结果显示,疫苗引入后腹泻住院比例从接种前年中位数26%降至2016年的16%,轮状病毒阳性率从接种前的56%降至2016年的12%,全因腹泻和轮状病毒特异性住院均大幅下降。
要点
- 疫苗引入后腹泻住院比例从接种前年中位数26%降至2015年17%、2016年16%。
- 轮状病毒阳性率从接种前56%降至2015年13%、2016年12%。
- 接种前常见基因型为G3P[8](66%)、G2P[4](15%)、G1P[8](14%);2015年最常见为G2P[4](67%)。
核心结论
- 轮状病毒疫苗引入后,全因腹泻和轮状病毒特异性住院均大幅下降。
研究设计与样本
- 2010年1月至2016年12月回顾医院入院登记簿,观察19619名5岁以下住院儿童中胃肠炎导致的住院率。
- 2013年6月至2016年12月在CHU MET开展主动轮状病毒监测,受世界卫生组织(WHO)支持。
- 采用EIA检测哨点实验室符合轮状病毒胃肠炎监测条件儿童的粪便标本轮状病毒抗原,阳性标本在区域参考实验室通过RT-PCR进行基因分型。
主要发现
- 疫苗引入前腹泻导致的年住院比例中位数为26%(范围:31-22%);疫苗引入当年为25%,2015年为17%,2016年为16%。
- 疫苗引入前56%的粪便标本轮状病毒检测阳性;2015年阳性率为13%,2016年为12%。
- 疫苗引入前检出多种基因型,最常见为G3P[8](n=53;66%)、G2P[4](n=12;15%)和G1P[8](n=11;14%)。
- 2015年发现6种不同基因型,最常见为G2P[4](n=10;67%),其余5种G12[P8]、G3[P8]、G1G3[P4]、G3G12[P4][P8]和G1G3[NT]各检出1份阳性标本。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rotavirus vaccine was introduced into the Extended Program on Immunization in Madagascar in May 2014. We analyzed trends in prevalence of all cause diarrhea and rotavirus hospitalization in children <5years of age before and after vaccine introduction and assessed trend of circulating rotavirus genotypes at Centre Hospitalier Universitaire Mère Enfant Tsaralalàna (CHU MET). METHODS: From January 2010 to December 2016, we reviewed the admission logbook to observe the rate of hospitalization caused by gastroenteritis among 19619 children <5years of age admitted at the hospital. In June 2013-December 2016, active rotavirus surveillance was also conducted at CHUMET with support from WHO. Rotavirus antigen was detected by EIA from stool specimen of children who are eligible for rotavirus gastroenteritis surveillance at sentinel site laboratory and rotavirus positive specimens were further genotyped at Regional Reference Laboratory by RT-PCR. RESULTS: Diarrhea hospitalizations decreased after rotavirus vaccine introduction. The median proportion of annual hospitalizations due to diarrhea was 26% (range: 31-22%) before vaccine introduction; the proportion was 25% the year of vaccine introduction, 17% in 2015 and 16% in 2016. Rotavirus positivity paralleled patterns observed in diarrhea. Before vaccine introduction, 56% of stool specimens tested positive for rotavirus; the percent positive was 13% in 2015, 12% in 2016. Diverse genotypes were detected in the pre-vaccine period; the most common were G3P[8] (n=53; 66%), G2P[4] (n=12; 15%), and G1P[8] (n=11; 14%). 6 distinct genotypes were found in 2015; the most common genotype was G2P[4] (n=10; 67%), the remaining, 5, G12[P8], G3[P8], G1G3[P4], G3G12[P4][P8] and G1G3[NT] had one positive specimen each. CONCLUSIONS: Following rotavirus vaccine introduction all-cause diarrhea and rotavirus-specific hospitalizations declined dramatically. The most common genotypes detected in the pre-vaccine period were G3P[8] and G2P[4] in 2015, the post vaccine period.
引用
- Rahajamanana VL, Raboba JL, Rakotozanany A, et al. Impact of rotavirus vaccine on all-cause diarrhea and rotavirus hospitalizations in Madagascar. Vaccine. 2017. PMID: 28958809. doi:10.1016/j.vaccine.2017.08.091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。